{
  "meta": {
    "id": "test24",
    "title": "Coagulation Pathways & Disorders",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "All of the following statement(s) is/are correct except:",
      "options": [
        {
          "label": "A",
          "text": "Increased PT in extrinsic pathways",
          "correct": false
        },
        {
          "label": "B",
          "text": "Increased aPTT in intrinsic pathways",
          "correct": false
        },
        {
          "label": "C",
          "text": "If the platelet count is > 1.5 lac/microL, then normal homeostasis is present",
          "correct": false
        },
        {
          "label": "D",
          "text": "BT is normal in platelet abnormality",
          "correct": true
        }
      ],
      "correct_answer": "D. BT is normal in platelet abnormality",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>BT is normal in platelet abnormality Bleeding time measures the function of platelets and so will be increased in platelet abnormality. Bleeding time (BT) (normal: 3-8 min) Q \u25cf       Time taken for a standardized skin puncture to stop bleeding. \u25cf       Tests the ability of vessels to vasoconstrict & platelets to form a hemostatic plug.</p>\n<p><strong>Highyeild:</strong></p><p>The prothrombin time (PT) assay assesses the function of the proteins in the extrinsic pathway (factors VII, X, V, II [prothrombin], and fibrinogen) . In brief, tissue factor, phospholipids, and calcium are added to plasma, and the time for a fibrin clot to form is recorded.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Increased PT in extrinsic pathways. Correct . Option: B. Increased aPTT in intrinsic pathways. Correct . Option: C. If the platelet count is > 1.5 lac/microL, then normal homeostasis is present. Correct .</p>\n<p><strong>Extraedge:</strong></p><p>The partial thromboplastin time (PTT) assay screens the function of the proteins in the intrinsic pathway (factors XII, XI, IX, VIII, X, V, II, and fibrinogen) . In this assay, clotting of plasma is initiated by the addition of negatively charged particles (e.g., ground glass) that activates factor XII (Hageman factor) together with phospholipids and calcium, and the time to fibrin clot formation is recorded.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "410b3827",
      "audio": ""
    },
    {
      "text": "Which of the following measures the intrinsic pathway?",
      "options": [
        {
          "label": "A",
          "text": "CT",
          "correct": false
        },
        {
          "label": "B",
          "text": "aPTT",
          "correct": true
        },
        {
          "label": "C",
          "text": "TT",
          "correct": false
        },
        {
          "label": "D",
          "text": "Prothrombin time",
          "correct": false
        }
      ],
      "correct_answer": "B. aPTT",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>aPTT Activated Partial thromboplastin time (aPTT) Q time taken for clotting when Kaolin/Silica is added to activate intrinsic pathway Q Other Other TESTS USED TO EVALUATE BLEEDING AND COAGULATION DISORDERS Test Description & Significance Tourniquet test (Hess test) Q \u25cf       BP cuff inflated to above diastolic pressure for 5 minutes \u25cf       Appearance of\u2265 20 petechiae Q in 1 sq inch area of forearm indicates capillary fragility, thrombocytopenia, or platelet abnormalities. Clotting time (CT) (normal: 5-10 min) Q \u25cf       Time taken for the patient's blood to clot in a test tube. \u25cf       Very insensitive test ; Not used now a days. Clot retraction failure of clot retraction in 1\u20134 hours indicates thrombocytopenia or abnormal platelet function Q. Prothrombin time (PT)Q time taken for clotting to occur when tissue thromboplastin Q (brain extract) and calcium are added to the patient's plasma to activate extrinsic pathway Q Thrombin time (TT): time taken for clotting when thrombin is added to the patient's plasma to test for conversion of fibrinogen to fibrin (depends on fibrinogen levels) Q</p>\n<p><strong>Highyeild:</strong></p><p>The prothrombin time (PT) assay assesses the function of the proteins in the extrinsic pathway (factors VII, X, V, II [prothrombin], and fibrinogen) . In brief, tissue factor, phospholipids, and calcium are added to plasma, and the time for a fibrin clot to form is recorded.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. CT. Clotting time, the time taken for a patient\u2019s blood to clot in a day, is not used nowadays. Option: C. TT. Thrombin time is the time taken when thrombin is added to a patient's plasma for conversion of fibrinogen to fibrin (depending on fibrinogen levels). Option: D. Prothrombin time. Time is taken for clotting to occur when tissue thromboplastin and calcium are added to a patient's plasma to activate the extrinsic pathway.</p>\n<p><strong>Extraedge:</strong></p><p>The partial thromboplastin time (PTT) assay screens the function of the proteins in the intrinsic pathway (factors XII, XI, IX, VIII, X, V, II, and fibrinogen) . In this assay, clotting of plasma is initiated by the addition of negatively charged particles (e.g., ground glass) that activates factor XII (Hageman factor) together with phospholipids and calcium, and the time to fibrin clot formation is recorded.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ac7c91d5",
      "audio": ""
    },
    {
      "text": "Which of the following factors helps to stabilize the clot but does not cause spontaneous bleeding if deficient?",
      "options": [
        {
          "label": "A",
          "text": "VIII",
          "correct": false
        },
        {
          "label": "B",
          "text": "XIII",
          "correct": false
        },
        {
          "label": "C",
          "text": "IX",
          "correct": false
        },
        {
          "label": "D",
          "text": "XII",
          "correct": true
        }
      ],
      "correct_answer": "D. XII",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>XII Factor XII deficiency usually is not associated with hemorrhagic manifestations . It is noteworthy that myocardial infarction and thrombophlebitis have been observed in patients with severe factor XII deficiency, and that Hageman died of thromboembolic complications. It was originally thought that factor XII deficiency might actually predispose to thrombosis, possibly as the result of deficient the activation of fibrinolysis. However, more recent surveys indicate that factor XII deficiency is not associated with an excessive risk of thrombosis ; thrombotic events in factor XII\u2013deficient patients may be explained by the presence of other prothrombotic gene defects in these patients.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. VIII. Causes Hemophilia A . Option: B. XIII. Deficiency of factor XIII leads to impaired clot stability , which can result in a bleeding disorder . Option: C. IX. Causes Hemophilia B.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "df9120e1",
      "audio": ""
    },
    {
      "text": "An 11-year-old boy has elevated prothrombin and activated partial prothrombin time. What is the most likely defect?",
      "options": [
        {
          "label": "A",
          "text": "Defect in the extrinsic pathway",
          "correct": false
        },
        {
          "label": "B",
          "text": "Defect in the intrinsic pathway",
          "correct": false
        },
        {
          "label": "C",
          "text": "Defect in a common pathway",
          "correct": true
        },
        {
          "label": "D",
          "text": "Defect in platelet function",
          "correct": false
        }
      ],
      "correct_answer": "C. Defect in a common pathway",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Defect in a common pathway activated Partial thromboplastin time (aPTT) 26-37 sec \u25cf Deficiencies or inhibitors of: Prekallikrein, high-molecular-weight kininogen Factors XII, XI, IX, VIII, X,V, II and I; \u25cf Lupus inhibitors; heparin ; warfarin therapy Prothrombin time (PT) 12-15 sec \u25cf Deficiencies or inhibitors of factors VII, X, and V; II and I; Q \u25cf       Lupus inhibitors; heparin; warfarin Q So, increase in both PT and aPTT will be due to common pathway defect. (Factor X,V,II,I deficiency)</p>\n<p><strong>Highyeild:</strong></p><p>Prothrombin Time 12-16 sec Activated Partial Thromboplastin Time 28-35 sec Measure EP + CP IP + CP Sample PPP {Platelet Poor Plasma} PPP Add in Thromboplastin Ca + PL Kaolin Ca + PL 1. \u2191 PT Normal APTT - Extrinsic Pathway defect; Factor VII deficiency: Vit-K deficiency: Warfarin II. Norml PT \u2191 APTT Intrinsic Pathway deficiency: Factor XII, XI, IX, VIII deficiency; Von Willebrand Disease III. 1PT \u2191 APTT - Common Pathway defect: Factor X, V, II, I deficiency: Severe Liver disease; DIC</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Defect in the extrinsic pathway. Incorrect . Option: B. Defect in the intrinsic pathway. Incorrect . Option: D. Defect in platelet function. Incorrect .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "936443bb",
      "audio": ""
    },
    {
      "text": "Which of the following is the most reliable test for screening haemophilia?",
      "options": [
        {
          "label": "A",
          "text": "Prothrombin time",
          "correct": false
        },
        {
          "label": "B",
          "text": "Clotting time",
          "correct": false
        },
        {
          "label": "C",
          "text": "Partial thromboplastin time",
          "correct": true
        },
        {
          "label": "D",
          "text": "Clot retraction",
          "correct": false
        }
      ],
      "correct_answer": "C. Partial thromboplastin time",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Partial thromboplastin time Hemophilia A and B are due to deficiency of Factor VIII and IX respectively, so aPTT is the best test. activated Partial thromboplastin time (aPTT) 26-37 sec \u25cf Deficiencies or inhibitors of: Prekallikrein, high-molecular-weight kininogen Factors XII, XI, IX, VIII, X,V, II and I; \u25cf Lupus inhibitors; heparin ; warfarin therapy Hemophillia A and B is due to deficiency of Factor VIII, IX so aptt is the best test.</p>\n<p><strong>Highyeild:</strong></p><p>Hemophilia A (Factor VIII Deficiency) Hemophilia A, the most common hereditary disease associated with life-threatening bleeding , is caused by mutations in factor VIII , an essential cofactor for factor IX in the coagulation cascade. Hemophilia A is inherited as an X-linked recessive trait and thus affects mainly males and homozygous females . In all symptomatic cases, there is a tendency toward easy bruising and massive haemorrhage after trauma or operative procedures. In addition, spontaneous haemorrhages frequently occur in regions of the body that are susceptible to trauma, particularly the joints , where they are known as hemarthroses . Recurrent bleeding into the joints leads to progressive deformities that can be crippling.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Prothrombin time. Incorrect . Option: B. Clotting time. Incorrect . Option: D. Clot retraction. Incorrect .</p>\n<p><strong>Extraedge:</strong></p><p>Petechiae are characteristically absent . Patients with haemophilia A have a prolonged PTT and a normal PT , results that point to an abnormality of the intrinsic coagulation pathway. Hemophilia A is treated with infusions of recombinant factor VIII .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9f840da3",
      "audio": ""
    },
    {
      "text": "vWF protects factor?",
      "options": [
        {
          "label": "A",
          "text": "II",
          "correct": false
        },
        {
          "label": "B",
          "text": "V",
          "correct": false
        },
        {
          "label": "C",
          "text": "VIII",
          "correct": true
        },
        {
          "label": "D",
          "text": "X",
          "correct": false
        }
      ],
      "correct_answer": "C. VIII",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>VIII vWF is required for normal platelet adhesion and also acts as a carrier of factor VIII in the plasma 2 major functions of vWF are Platelet adhesion via GpIb/IX and stabilising factor VIII in circulation.</p>\n<p><strong>Highyeild:</strong></p><p>Features von Willebrand Disease Bernard Soulier Syndrome Glanzmann\u2019s Thrombasthenia Inheritance Autosomal dominant Autosomal Recessive Autosomal Recessive Defects Type 1 and 3: Quantitative defects in vWF. Type 2 Qualitative defects in vWF. Absence of Gp Ib-IX-V receptor Absence of Gp IIb/IIIa receptor Mechanism Platelet adhesion defect despite having normal platelet counts. Factor VIII deficiency as vWF prevents degradation of factor VIII. Platelets adhesion defect. Platelet aggregation defect. Platelet counts Normal Normal/ Mild thrombocytopenia Normal Platelet morphology Normal Large platelets with dense granules Normal Bleeding time Prolonged Prolonged Prolonged Platelets aggregation test (Collagen, ADP, Thrombin) Normal Normal Abnormal Ristocetin Aggregation test Abnormal Normalises after the addition of normal serum . Abnormal Doesn\u2019t normalise after the addition of normal serum . Normal vWF factor levels Decreased Normal Normal PT and aPTT Normal PT and prolonged aPTT Normal Normal MNEMONIC: B comes before G which is why Bernard Soullier shows the absence of Ib and Glanzmann Thrombasthenia shows the absence of IIb .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. II. Incorrect . Option: B. V. Incorrect . Option: D. X. Incorrect .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "399a5f2c",
      "audio": ""
    },
    {
      "text": "10-day infant presented with large cephalic hematoma. His parents gave no history of trauma but severe umbilical bleeding during his childbirth. What is the most likely factor deficiency associated?",
      "options": [
        {
          "label": "A",
          "text": "vWF",
          "correct": false
        },
        {
          "label": "B",
          "text": "Factor I def",
          "correct": false
        },
        {
          "label": "C",
          "text": "Factor VIII def",
          "correct": false
        },
        {
          "label": "D",
          "text": "Factor XIII def",
          "correct": true
        }
      ],
      "correct_answer": "D. Factor XIII def",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Factor XIII def Factor XIII deficiency: Signs and symptoms of inherited factor XIII deficiency begin soon after birth , usually with abnormal bleeding from the umbilical cord stump . If the conditio13th not treated, affected individuals may have episodes of excessive and prolonged bleeding that can be life-threatening . Abnormal bleeding can occur after surgery or minor trauma. The condition can also cause spontaneous bleeding into the joints or muscles, leading to pain and disability . Women with inherited factor XIII deficiency tend to have heavy or prolonged menstrual bleeding (menorrhagia) and may experience recurrent pregnancy losses (miscarriages) . Other signs and symptoms of inherited factor XIII deficiency include nosebleeds, bleeding of the gums, easy bruising, problems with wound healing, and abnormal scar formation.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. vWF. von Willebrand disease (vWD), which is caused by a deficiency or dysfunction of von Willebrand factor, is typically characterized by mucocutaneous bleeding, such as nosebleeds or gum bleeding, rather than soft tissue bleeding . Option: B. Factor I def. Factor I deficiency , also known as fibrinogen deficiency , can lead to abnormal bleeding and impaired clotting but is less likely to cause a cephalic hematoma in a newborn. Option: C. Factor VIII def. Factor VIII dehaemorrhage and cause bleeding in newborns, it is less likely to present with a cephalic hematoma without a history of trauma.</p>\n<p><strong>Extraedge:</strong></p><p>Inherited factor XIII deficiency also increases the risk of spontaneous bleeding inside the skull (intracranial h aemorrhage), which is the leading cause of death in people with this condition .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "21c11c18",
      "audio": ""
    },
    {
      "text": "Which of the following is not a platelet-associated coagulation factor?",
      "options": [
        {
          "label": "A",
          "text": "vWF",
          "correct": false
        },
        {
          "label": "B",
          "text": "Factor IX",
          "correct": true
        },
        {
          "label": "C",
          "text": "Factor XI",
          "correct": false
        },
        {
          "label": "D",
          "text": "Factor XIII",
          "correct": false
        }
      ],
      "correct_answer": "B. Factor IX",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Factor IX Platelet-associated coagulation factors are: Fibrinogen, vWF, Factor V, XI, XIII & HMWK</p>\n<p><strong>Highyeild:</strong></p><p>Vitamin K-dependent coagulation factors : Factors II, VII, IX, and X . In Vitamin K deficiency and Warfarin usage: Factor 7 deficiency is first to decrease .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Incorrect . Option: C. Factor XI. Incorrect . Option: D. Factor XIII. Incorrect .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6bedfee2",
      "audio": ""
    },
    {
      "text": "Hemophilia C is a deficiency of",
      "options": [
        {
          "label": "A",
          "text": "Factor VIII",
          "correct": false
        },
        {
          "label": "B",
          "text": "Factor IX",
          "correct": false
        },
        {
          "label": "C",
          "text": "Factor X",
          "correct": false
        },
        {
          "label": "D",
          "text": "Factor XI",
          "correct": true
        }
      ],
      "correct_answer": "D. Factor XI",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Factor XI Hemophilia C is Factor XI deficiency</p>\n<p><strong>Highyeild:</strong></p><p>Hemophilia: The most common and important inherited deficiencies of coagulation factors affect factor VIII (haemophilia A) and factor IX (haemophilia B) . Hemophilia A (Factor VIII Deficiency) Hemophilia A , the most common hereditary disease associated with life-threatening bleeding, is caused by mutations in factor VIII , an essential cofactor for factor IX in the coagulation cascade. Hemophilia A is inherited as an X-linked recessive trait and thus affects mainly males and homozygous females . There is a tendency for easy bruising and massive haemorrhage after trauma or operative procedures . In addition, \u201cspontaneous\u201d haemorrhages frequently occur in regions of the body that are susceptible to trauma, particularly the joints , where they are known as hemarthroses . Recurrent bleeding into the joints leads to progressive deformities that can be crippling. Petechiae are characteristically absent . Patients with haemophilia A have a prolonged PTT and a normal PT . Factor VIII\u2013specific assays are required for diagnosis. Hemophilia A is treated with infusions of recombinant factor VIII . Hemophilia B (Christmas Disease, Factor IX Deficiency) Severe factor IX deficiency produces a disorder clinically indistinguishable from factor VIII deficiency (haemophilia A). This should not be surprising, given that factors VIII and IX function together to activate factor It is inherited as an X-linked recessive trait . In about 15% of these patients, factor IX protein is present but is nonfunctional. As with haemophilia A, the PTT is prolonged and the PT is normal .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Factor VIII. Deficiency causes Hemophilia A . Option: B. Factor IX. Deficiency causes Hemophilia B/ Christmas Disease . Option: C. Factor X. Incorrect .</p>\n<p><strong>Extraedge:</strong></p><p>Diagnosis of Christmas disease (named after the first patient identified with this condition, and not the holiday) is possible only by assay of the factor levels . The disease is treated with infusions of recombinant factor IX .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c1fd6e77",
      "audio": ""
    },
    {
      "text": "Levels of all coagulation factors are increased in pregnancy EXCEPT",
      "options": [
        {
          "label": "A",
          "text": "Factor VIII",
          "correct": false
        },
        {
          "label": "B",
          "text": "Factor IX",
          "correct": false
        },
        {
          "label": "C",
          "text": "Factor X",
          "correct": false
        },
        {
          "label": "D",
          "text": "Factor XI",
          "correct": true
        }
      ],
      "correct_answer": "D. Factor XI",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Factor XI Levels of factor XI are decreased in pregnancy.</p>\n<p><strong>Highyeild:</strong></p><p>In pregnancy, Factor II & V remain unchanged Factor XI & XIII are decreased Other coagulation factors increase making pregnancy a hypercoagulable state .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Factor VIII. Increased . Option: B. Factor IX. Increased . Option: C. Factor X. Increased .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a7cffd6b",
      "audio": ""
    },
    {
      "text": "Causes for DIC are all except:",
      "options": [
        {
          "label": "A",
          "text": "Anaerobic sepsis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Malignancy",
          "correct": false
        },
        {
          "label": "C",
          "text": "Lymphoma",
          "correct": true
        },
        {
          "label": "D",
          "text": "Leukemia",
          "correct": false
        }
      ],
      "correct_answer": "C. Lymphoma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Lymphoma Lymphoma is not the cause for DIC.</p>\n<p><strong>Highyeild:</strong></p><p>DIC is an acute, subacute, or chronic thrombo-hemorrhagic disorder characterized by the excessive activation of coagulation and the formation of thrombi in the microvasculature. It occurs as a secondary complication of many disorders. Sometimes the coagulopathy is localized to a specific organ or tissue. As a consequence of the thrombotic diathesis , there is the consumption of platelets, fibrin, and coagulation factors and, secondarily , activation of fibrinolysis . DIC can present with signs and symptoms relating to tissue hypoxia and infarction caused by microthrombi ; haemorrhage , due to depletion of factors required for hemostasis and activation of fibrinolytic mechanisms; or both. Two major mechanisms trigger DIC: Release of tissue factor or other procoagulants into the circulation. Widespread injury of endothelial cells. Common triggers: sepsis, major trauma, certain cancers, and obstetric complications . Etiology of DIC: table,tr,th,td {border:1px solid black;} Sepsis Immunologic disorders Bacterial: Staphylococci Q , streptococci, pneumococci, meningococci Q, gram-negative bacilli Q Viral, Mycotic, Parasitic, Rickettsial Q Acute hemolytic transfusion reaction, Transplant rejection, GVHD Q Trauma and tissue injury Drugs Brain injury (gunshot),Extensive burns, Fat embolism, Rhabdomyolysis Fibrinolytic agents, Warfarin (especially in neonates with protein C deficiency) Vascular disorders Envenomation Giant hemangiomas (Kasabach-Merritt syndrome)Q Snake, Insect bites Obstetrical complications Liver disease Abruptio placentae Q, Amniotic-fluid embolism, Dead fetus syndrome, Septic abortion Q Fulminant hepatic failure Q Cirrhosis, Fatty liver of pregnancy Q Cancer Miscellaneous Stomach Ca, Lung Ca, Acute promyelocytic leukemia (APML) Q Pancreas (most common) & Prostate Adenocarcinoma Q Shock, Respiratory distress syndrome, Massive transfusion Q</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Anaerobic sepsis. Correct . Option: B. Malignancy. Correct . Option: D. Leukemia. Correct .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cad48a95",
      "audio": ""
    },
    {
      "text": "Disseminated intravascular coagulation (DIC) differs from thrombotic thrombocytopenic purpura by-",
      "options": [
        {
          "label": "A",
          "text": "Significant numbers of schistocytes",
          "correct": false
        },
        {
          "label": "B",
          "text": "A brisk reticulocytosis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Decreased coagulation factor levels",
          "correct": true
        },
        {
          "label": "D",
          "text": "Significant thrombocytopenia",
          "correct": false
        }
      ],
      "correct_answer": "C. Decreased coagulation factor levels",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Decreased coagulation factor levels Correct, seen only in DIC not in TTP .</p>\n<p><strong>Highyeild:</strong></p><p>DIC is an acute, subacute, or chronic thrombohemorrhagic disorder characterized by the excessive activation of coagulation and the formation of thrombi in the microvasculature. It occurs as a secondary complication of many disorders. Sometimes the coagulopathy is localized to a specific organ or tissue. As a consequence of the thrombotic diathesis , there is the consumption of platelets, fibrin, and coagulation factors and, secondarily , the activation of fibrinolysis . DIC can present with signs and symptoms relating to tissue hypoxia and infarction caused by microthrombi ; haemorrhage , due to depletion of factors required for hemostasis and activation of fibrinolytic mechanisms; or both. Two major mechanisms trigger DIC: Release of tissue factor or other procoagulants into the circulation. Widespread injury of endothelial cells. Common triggers: sepsis, major trauma, certain cancers, and obstetric complications .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Significant numbers of schistocytes. Seen in both, as both are causes of Microangiopathic hemolytic anaemia . Option: B. A brisk reticulocytosis. Seen in both, as both are causes of Microangiopathic hemolytic anaemia . Option: D. Significant thrombocytopenia. Seen in both.</p>\n<p><strong>Extraedge:</strong></p><p>Etiology of DIC: Sepsis Immunologic disorders Bacterial: Staphylococci Q , streptococci, pneumococci, meningococci Q, gram-negative bacilli Q Viral, Mycotic, Parasitic, Rickettsial Q Acute hemolytic transfusion reaction, Transplant rejection, GVHD Q Trauma and tissue injury Drugs Brain injury (gunshot),Extensive burns, Fat embolism, Rhabdomyolysis Fibrinolytic agents, Warfarin (especially in neonates with protein C deficiency) Vascular disorders Envenomation Giant hemangiomas (Kasabach-Merritt syndrome)Q Snake, Insect bites Obstetrical complications Liver disease Abruptio placentae Q, Amniotic-fluid embolism, Dead fetus syndrome, Septic abortion Q Fulminant hepatic failure Q Cirrhosis, Fatty liver of pregnancy Q Cancer Miscellaneous Stomach Ca, Lung Ca, Acute promyelocytic leukemia (APML) Q Pancreas (most common) & Prostate Adenocarcinoma Q Shock, Respiratory distress syndrome, Massive transfusion Q</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "391d7fe3",
      "audio": ""
    },
    {
      "text": "Not a cause for DIC -",
      "options": [
        {
          "label": "A",
          "text": "Septicemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Visceral carcinoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cholera",
          "correct": true
        },
        {
          "label": "D",
          "text": "Antepartum haemorrhage",
          "correct": false
        }
      ],
      "correct_answer": "C. Cholera",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Cholera Cholera is not a cause for DIC.</p>\n<p><strong>Highyeild:</strong></p><p>DIC is an acute, subacute, or chronic thrombohemorrhagic disorder characterized by the excessive activation of coagulation and the formation of thrombi in the microvasculature. It occurs as a secondary complication of many disorders. Sometimes the coagulopathy is localized to a specific organ or tissue. As a consequence of the thrombotic diathesis , there is the consumption of platelets, fibrin, and coagulation factors and, secondarily , the activation of fibrinolysis . DIC can present with signs and symptoms relating to tissue hypoxia and infarction caused by microthrombi ; haemorrhage , due to depletion of factors required for hemostasis and activation of fibrinolytic mechanisms; or both. Two major mechanisms trigger DIC: Release of tissue factor or other procoagulants into the circulation. Widespread injury of endothelial cells. Common triggers: sepsis, major trauma, certain cancers, and obstetric complications .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Septicemia. Correct . Option: B. Visceral carcinoma. Correct . Option: D. Antepartum haemorrhage. Correct .</p>\n<p><strong>Extraedge:</strong></p><p>Etiology of DIC: Sepsis Immunologic disorders Bacterial: Staphylococci Q , streptococci, pneumococci, meningococci Q, gram-negative bacilli Q Viral, Mycotic, Parasitic, Rickettsial Q Acute hemolytic transfusion reaction, Transplant rejection, GVHD Q Trauma and tissue injury Drugs Brain injury (gunshot),Extensive burns, Fat embolism, Rhabdomyolysis Fibrinolytic agents, Warfarin (especially in neonates with protein C deficiency) Vascular disorders Envenomation Giant hemangiomas (Kasabach-Merritt syndrome)Q Snake, Insect bites Obstetrical complications Liver disease Abruptio placentae Q, Amniotic-fluid embolism, Dead fetus syndrome, Septic abortion Q Fulminant hepatic failure Q Cirrhosis, Fatty liver of pregnancy Q Cancer Miscellaneous Stomach Ca, Lung Ca, Acute promyelocytic leukemia (APML) Q Pancreas (most common) & Prostate Adenocarcinoma Q Shock, Respiratory distress syndrome, Massive transfusion Q</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7e4eb1e2",
      "audio": ""
    },
    {
      "text": "Bleeding in DIC is most closely related to -",
      "options": [
        {
          "label": "A",
          "text": "Raised fibrin degradation products level in blood",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prolong prothrombin time",
          "correct": false
        },
        {
          "label": "C",
          "text": "Low serum fibrinogen level",
          "correct": true
        },
        {
          "label": "D",
          "text": "Raised thrombin time",
          "correct": false
        }
      ],
      "correct_answer": "C. Low serum fibrinogen level",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Low serum fibrinogen level Bleeding in DIC is most closely related to low fibrinogen level s in the blood and so the main aim of replacement therapy with blood products (FFP) in DIC is to replenish Fibrinogen .</p>\n<p><strong>Highyeild:</strong></p><p>DIC is an acute, subacute, or chronic thrombohemorrhagic disorder characterized by the excessive activation of coagulation and the formation of thrombi in the microvasculature. It occurs as a secondary complication of many disorders. Sometimes the coagulopathy is localized to a specific organ or tissue. As a consequence of the thrombotic diathesis , there is the consumption of platelets, fibrin, and coagulation factors and, secondarily , the activation of fibrinolysis . DIC can present with signs and symptoms relating to tissue hypoxia and infarction caused by microthrombi ; haemorrhage , due to depletion of factors required for hemostasis and activation of fibrinolytic mechanisms; or both. Two major mechanisms trigger DIC: Release of tissue factor or other procoagulants into the circulation. Widespread injury of endothelial cells. Common triggers: sepsis, major trauma, certain cancers, and obstetric complications .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Septicemia. Correct . Option: B. Visceral carcinoma. Correct . Option: D. Antepartum haemorrhage. Correct .</p>\n<p><strong>Extraedge:</strong></p><p>Etiology of DIC: Sepsis Immunologic disorders Bacterial: Staphylococci Q , streptococci, pneumococci, meningococci Q, gram-negative bacilli Q Viral, Mycotic, Parasitic, Rickettsial Q Acute hemolytic transfusion reaction, Transplant rejection, GVHD Q Trauma and tissue injury Drugs Brain injury (gunshot),Extensive burns, Fat embolism, Rhabdomyolysis Fibrinolytic agents, Warfarin (especially in neonates with protein C deficiency) Vascular disorders Envenomation Giant hemangiomas (Kasabach-Merritt syndrome)Q Snake, Insect bites Obstetrical complications Liver disease Abruptio placentae Q, Amniotic-fluid embolism, Dead fetus syndrome, Septic abortion Q Fulminant hepatic failure Q Cirrhosis, Fatty liver of pregnancy Q Cancer Miscellaneous Stomach Ca, Lung Ca, Acute promyelocytic leukemia (APML) Q Pancreas (most common) & Prostate Adenocarcinoma Q Shock, Respiratory distress syndrome, Massive transfusion Q</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0ed63edc",
      "audio": ""
    },
    {
      "text": "Antithrombin is activated by:",
      "options": [
        {
          "label": "A",
          "text": "Heparin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Factor I",
          "correct": false
        },
        {
          "label": "C",
          "text": "Factor V",
          "correct": false
        },
        {
          "label": "D",
          "text": "Factor VIII",
          "correct": false
        }
      ],
      "correct_answer": "A. Heparin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Heparin Antithrombin , a serine protease inhibitor, regulates coagulation by inactivating thrombin and other procoagulant enzymes, including factors Xa, IXa, XIa, and XIIa. Once bound to Heparin , the natural anticoagulant effect of Antithrombin is potentiated , resulting in the accelerated binding and inactivation of serine proteases, and factor Xa and thrombin in particular. The inhibition of these factors affects the common pathway of coagulation , resulting in decreased formation of thrombin and fibrin .</p>\n<p><strong>Highyeild:</strong></p><p>Prothrombin Time 12-16 sec Activated Partial Thromboplastin Time 28-35 sec Measure EP + CP IP + CP Sample PPP {Platelet Poor Plasma} PPP Add in Thromboplastin Ca + PL Kaolin Ca + PL I.            s\u2191 PT Normal APTT - Extrinsic Pathway defect; Factor VII deficiency: Vit-K deficiency: Warfarin II.            Norml PT \u2191 APTT - Intrinsic Pathway deficiency; Factor XII, XI, IX, VIII deficiency: Von Willebrand Disease III.            \u2191 PT \u2191 APTT - Common Pathway defect: Factor X, V. II, I deficiency: Severe Liver disease; DIC</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: B. Factor I. Incorrect . Option: C. Factor V. Incorrect . Option: D. Factor VIII. Incorrect .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b29f839a",
      "audio": ""
    },
    {
      "text": "Tumours causing thrombosis are all except:",
      "options": [
        {
          "label": "A",
          "text": "Stomach",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lung",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pancreas",
          "correct": false
        },
        {
          "label": "D",
          "text": "Breast",
          "correct": true
        }
      ],
      "correct_answer": "D. Breast",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Breast Thrombosis is breast carcinoma is the least common among the given Options.</p>\n<p><strong>Highyeild:</strong></p><p>Cancer-causing thrombosis are Stomach Ca, Lung Ca, Acute promyelocytic leukaemia (APML) M3 , Pancreas ( most common ) & Prostate Adenocarcinoma . MNEMONIC: SLAP tumours cause thrombosis .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Stomach. Causes thrombosis . Option: B. Lung. Causes thrombosis . Option: C. Pancreas. Causes thrombosis .</p>\n<p><strong>Extraedge:</strong></p><p>Table 4.2 Hypercoagulable States Primary (Genetic) Common Factor V mutation: factor V Leiden (Arg to Gln substitution in amino acid residue 506 leading to resistance to activated protein C) Prothrombin mutation (G20210A noncoding sequence variant leading to increased prothrombin levels) Increased levels of factors VIII, IX, XI, or fibrinogen (genetics unknown) Rare Antithrombin III deficiency Protein C deficiency Protein S deficiency Very Rare Fibrinolysis defects Homozygous homocystinuria (deficiency of cystathione B-synthetase) Secondary (Acquired) Strong Risk Factors for Thrombosis Prolonged bed rest or immobilization Myocardial infarction Atrial fibrillation Tissue injury (surgery, fracture, burn) Cancer Prosthetic cardiac valves Disseminated intravascular coagulation Heparin-induced thrombocytopenia Antiphospholipid antibody syndrome Other Risk Factors for Thrombosis Cardiomyopathy Nephrotic syndrome Hyperestrogenic states (pregnancy and postpartum) Oral contraceptive use Sickle cell anemia Smoking</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2cb753ef",
      "audio": ""
    },
    {
      "text": "Treatment of antiphospholipid antibody syndrome:",
      "options": [
        {
          "label": "A",
          "text": "Warfarin for life",
          "correct": true
        },
        {
          "label": "B",
          "text": "Warfarin for 1 year",
          "correct": false
        },
        {
          "label": "C",
          "text": "IV immunoglobulin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Glucocorticoids",
          "correct": false
        }
      ],
      "correct_answer": "A. Warfarin for life",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Warfarin for life After the first thrombotic event, APS patients should be placed on warfarin for life , aiming to achieve an international normalized ratio, INR , ranging from 2.5 to 3.5 , alone or in combination with 80 mg of aspirin daily . Pregnancy morbidity is prevented by a combination of heparin with aspirin 80 mg daily. IV immunoglobulin (IVIg) 400 mg/ kg every day for 5 days may also prevent abortions, whereas glucocorticoids are ineffective</p>\n<p><strong>Highyeild:</strong></p><p>Antiphospholipid antibody (APLA) This syndrome (previously called the lupus anticoagulant syndrome) has variable clinical manifestations, including recurrent thromboses, repeated miscarriages, cardiac valve vegetations, and thrombocytopenia . Fetal loss does not appear to be explained by thrombosis . Instead, it stems from antibody-mediated interference with the growth and differentiation of trophoblasts , leading to a failure of placentation. Antiphospholipid antibody syndrome is also a cause of renal microangiopathy , resulting in renal failure associated with multiple capillary and arterial thrombosis. Clinical presentations can include pulmonary embolism , pulmonary hypertension , valvular heart disease, stroke , bowel infarction , or renovascular hypertension . Anti\u2013\u03b22 -glycoprotein antibodies are suspected to have a significant role in APLA. Diagnosis of APLA is based on clinical features and demonstration of aPL antibodies in the serum. Management of APLA involves various forms of anticoagulation .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: B. Warfarin for 1 year. Incorrect . Option: C. IV immunoglobulin. Incorrect . Option: D. Glucocorticoids. Incorrect .</p>\n<p><strong>Extraedge:</strong></p><p>The antibodies in patients with APLA also frequently result in a false-positive serologic test for syphilis because the antigen in the standard assay is embedded in cardiolipin, which cross-reacts with phospholipids of Treponema pallidum.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ac7e7683",
      "audio": ""
    },
    {
      "text": "Not a feature of antiphospholipid antibody syndrome:",
      "options": [
        {
          "label": "A",
          "text": "Budd-Chiari syndrome",
          "correct": false
        },
        {
          "label": "B",
          "text": "Coombs positive hemolytic anaemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Libman sacks endocarditis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Priapism",
          "correct": true
        }
      ],
      "correct_answer": "D. Priapism",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Priapism Priapism is not a typical feature of antiphospholipid antibody syndrome (APS). APS is an autoimmune disorder characterized by the presence of antiphospholipid antibodies (APLA) that can cause a wide range of clinical manifestations. The clinical features of APS are related to the increased risk of thrombotic events and can include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, myocardial infarction, and recurrent pregnancy loss . Budd-Chiari syndrome, Coombs-positive hemolytic anaemia, and Libman-Sacks endocarditis are all well-known clinical features of APS .</p>\n<p><strong>Highyeild:</strong></p><p>Antiphospholipid antibody (APLA) This syndrome (previously called the lupus anticoagulant syndrome) has variable clinical manifestations, including recurrent thromboses, repeated miscarriages, cardiac valve vegetations, and thrombocytopenia . Fetal loss does not appear to be explained by thrombosis . Instead, it stems from antibody-mediated interference with the growth and differentiation of trophoblasts , leading to a failure of placentation. Antiphospholipid antibody syndrome is also a cause of renal microangiopathy , resulting in renal failure associated with multiple capillary and arterial thrombosis. Clinical presentations can include pulmonary embolism , pulmonary hypertension , valvular heart disease, stroke , bowel infarction , or renovascular hypertension . Anti\u2013\u03b22 -glycoprotein antibodies are suspected to have a significant role in APLA. Diagnosis of APLA is based on clinical features and demonstration of aPL antibodies in the serum. Management of APLA involves various forms of anticoagulation .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Budd-Chiari syndrome. Budd-Chiari syndrome is a rare condition that results from the obstruction of the hepatic veins, leading to liver congestion and liver failure . Coombs-positive Hemolytic ana Coombs-positive hemolytic anaemia is characterized by the destruction of red blood cells due to the production of autoantibodies . Option: C. Libman-Sacks endocarditis. Libman-Sacks endocarditis is a non-infectious inflammation of the heart valves that can lead to valve damage and heart failure .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "01ada136",
      "audio": ""
    },
    {
      "text": "All antibodies are seen in APLA except:",
      "options": [
        {
          "label": "A",
          "text": "Anti\u2013\u03b22 -glycoprotein",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anti-Prothrombin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Anti-Phospholipid",
          "correct": false
        },
        {
          "label": "D",
          "text": "Anti-Cardiolipin",
          "correct": false
        }
      ],
      "correct_answer": "B. Anti-Prothrombin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Anti-Prothrombin Anti-Prothrombin antibodies are not seen in APL A . Antibodies seen in APLA are Lupus Anticoagulant (LAC) Anti-cardiolipin (aCL) Anti\u2013\u03b22 -glycoprotein Lupus Anticoagulant (LAC) & Anti-cardiolipin (aCL) are antiphospholipid antibodies.</p>\n<p><strong>Highyeild:</strong></p><p>Antiphospholipid antibody (APLA) This syndrome (previously called the lupus anticoagulant syndrome) has variable clinical manifestations, including recurrent thromboses, repeated miscarriages, cardiac valve vegetations, and thrombocytopenia . Fetal loss does not appear to be explained by thrombosis . Instead, it stems from antibody-mediated interference with the growth and differentiation of trophoblasts , leading to a failure of placentation. Antiphospholipid antibody syndrome is also a cause of renal microangiopathy , resulting in renal failure associated with multiple capillary and arterial thrombosis. Clinical presentations can include pulmonary embolism , pulmonary hypertension , valvular heart disease, stroke , bowel infarction , or renovascular hypertension . Anti\u2013\u03b22 -glycoprotein antibodies are suspected to have a significant role in APLA.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Anti\u2013\u03b22 -glycoprotein. Correct . Option: C. Anti-Phospholipid. Correct . Option: D. Anti-Cardiolipin. Correct .</p>\n<p><strong>Extraedge:</strong></p><p>Diagnosis of APLA is based on clinical features and demonstration of aPL antibodies in the serum. Management of APLA involves various forms of anticoagulation .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "604289de",
      "audio": ""
    },
    {
      "text": "All are true about Virchow\u2019s triad except-",
      "options": [
        {
          "label": "A",
          "text": "Concerned with the risk of intravascular thrombus",
          "correct": false
        },
        {
          "label": "B",
          "text": "Depends on endothelial injury",
          "correct": false
        },
        {
          "label": "C",
          "text": "Depends on platelet activation",
          "correct": true
        },
        {
          "label": "D",
          "text": "Depends on stasis",
          "correct": false
        }
      ],
      "correct_answer": "C. Depends on platelet activation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Depends on platelet activation Virchow\u2019s triad does not depend upon platelet activation.</p>\n<p><strong>Highyeild:</strong></p><p>Thrombosis and Virchow\u2019s Triad: Thrombosis results due to: Endothelial injury Stasis or Turbulent blood flow Hypercoagulability of the blood This is called Virchow's Triad . Arterial or cardiac thrombi usually begin at turbulence or endothelial injury sites , whereas venous thrombi characteristically occur at stasis sites . Thrombi are focally attached to the underlying vascular surface , particularly at the initiation . From here, arterial thrombi tend to grow retrograde , while venous thrombi extend in the direction of blood flow ; thus, BOTH propagate towards the heart .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Concerned with the risk of intravascular thrombus. Correct . Option: B. Depends on the endothelial injury. Correct . Option: D. Depends on stasis. Correct .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4a78d95d",
      "audio": ""
    },
    {
      "text": "The Leiden factor is -",
      "options": [
        {
          "label": "A",
          "text": "Factor VI",
          "correct": false
        },
        {
          "label": "B",
          "text": "Factor VIII",
          "correct": false
        },
        {
          "label": "C",
          "text": "Factor IV",
          "correct": false
        },
        {
          "label": "D",
          "text": "Factor V",
          "correct": true
        }
      ],
      "correct_answer": "D. Factor V",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Factor V Leiden factor is factor V .</p>\n<p><strong>Highyeild:</strong></p><p>Factor V Leiden mutation is the most common cause of hypercoagulability. It is an autosomal dominant genetic condition that exhibits incomplete penetrance , meaning that not every person with the mutation will develop the disease. Single nucleotide mutation in factor V is called factor V Leiden . Among individuals with recurrent DVT , the frequency of this mutation is considerably higher, approaching 60% . The mutation results in the replacement of arginine with glutamine at amino acid 506 , which renders factor V resistant to cleavage and inactivation by protein C .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Factor VI. Incorrect . Option: B. Factor VIII. Incorrect . Option: C. Factor IV. Incorrect .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9413b16c",
      "audio": ""
    },
    {
      "text": "Coagulation normally is restricted to sites of vascular injury by:",
      "options": [
        {
          "label": "A",
          "text": "Circulating antithrombin III",
          "correct": false
        },
        {
          "label": "B",
          "text": "Activation of fibrinolytic pathways",
          "correct": false
        },
        {
          "label": "C",
          "text": "Activation of coagulation factors",
          "correct": true
        },
        {
          "label": "D",
          "text": "Expression of thrombomodulin",
          "correct": false
        }
      ],
      "correct_answer": "C. Activation of coagulation factors",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Activation of coagulation factors Coagulation normally is restricted to sites of vascular injury by: Limiting enzymatic activation to phospholipid surfaces provided by activated platelets or endothelium. Circulating inhibitors of coagulation factors, such as antithrombin III, whose activity is augmented by heparin-like molecules expressed on endothelial cells. Expression of thrombomodulin on normal endothelial cells, which binds thrombin and converts it to an anticoagulant. Activation of fibrinolytic pathways (e.g., by the association of t-PA with fibrin)</p>\n<p><strong>Highyeild:</strong></p><p>Normal endothelium shields coagulation factors from tissue factors in vessel walls and expresses multiple factors that actively oppose coagulation, most notably thrombomodulin , endothelial protein C receptor , heparin-like molecules , and tissue factor pathway inhibitor . Thrombomodulin and endothelial protein C receptor bind thrombin and protein C, respectively, in a complex on the endothelial cell surface. When bound in this complex, thrombin loses its ability to activate coagulation factors and platelets , and instead cleaves and activates protein C , a vitamin K\u2013dependent protease that requires a cofactor, protein S. Activated protein C/protein S complex is a potent inhibitor of coagulation cofactors Va and VIIIa .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Circulating antithrombin III. Correct . Option: B. Activation of fibrinolytic pathways. Correct . Option: D. Expression of thrombomodulin. Correct .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1dfce88d",
      "audio": ""
    },
    {
      "text": "International Normalised Ratio (INR) is defined as:",
      "options": [
        {
          "label": "A",
          "text": "(PT patient/ PT control)ISI",
          "correct": true
        },
        {
          "label": "B",
          "text": "(PT control/ PT patient)ISI",
          "correct": false
        },
        {
          "label": "C",
          "text": "(PT patient/ PT control)1/ISI",
          "correct": false
        },
        {
          "label": "D",
          "text": "(PT control/ PT patient)1/ISI",
          "correct": false
        }
      ],
      "correct_answer": "A. (PT patient/ PT control)ISI",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>(PT patient/ PT control)ISI By adjusting for the ISI of a particular thromboplastin, an INR is defined as the PT ratio that would have been obtained if the WHO standard thromboplastin had been used . INR is calculated using the following formula: INR = (PT patient/ PT control) ISI</p>\n<p><strong>Highyeild:</strong></p><p>Factor V Leiden mutation is the most common cause of hypercoagulability. It is an autosomal dominant genetic condition that exhibits incomplete penetrance , meaning that not every person with the mutation will develop the disease. Single nucleotide mutation in factor V is called factor V Leiden . Among individuals with recurrent DVT , the frequency of this mutation is considerably higher, approaching 60% . The mutation results in the replacement of arginine with glutamine at amino acid 506 , which renders factor V resistant to cleavage and inactivation by protein C .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: B. (PT control/ PT patient)ISI. Incorrect . Option: C. (PT patient/ PT control)1/ISI. Incorrect . Option: D. (PT control/ PT patient)1/ISI. Incorrect .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f2883649",
      "audio": ""
    },
    {
      "text": "Which of the following is not associated with increased prothrombin time?",
      "options": [
        {
          "label": "A",
          "text": "Severe factor seven deficiency",
          "correct": false
        },
        {
          "label": "B",
          "text": "Liver failure",
          "correct": false
        },
        {
          "label": "C",
          "text": "Von Willebrand disease",
          "correct": true
        },
        {
          "label": "D",
          "text": "DIC",
          "correct": false
        }
      ],
      "correct_answer": "C. Von Willebrand disease",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Von Willebrand disease In Von Willebrand\u2019s disease, there is a slight deficiency of Factor VIII leading to an increase in aPTT and not PT . Others can lead to an increase in PT.</p>\n<p><strong>Highyeild:</strong></p><p>Features von Willebrand Disease Bernard Soulier Syndrome Glanzmann\u2019s Thrombasthenia Inheritance Autosomal dominant Autosomal Recessive Autosomal Recessive Defects Type 1 and 3: Quantitative defects in vWF. Type 2 Qualitative defects in vWF. Absence of Gp Ib-IX-V receptor Absence of Gp IIb/IIIa receptor Mechanism Platelet adhesion defect despite having normal platelet counts. Factor VIII deficiency as vWF prevents degradation of factor VIII. Platelets adhesion defect. Platelet aggregation defect. Platelet counts Normal Normal/ Mild thrombocytopenia Normal Platelet morphology Normal Large platelets with dense granules Normal Bleeding time Prolonged Prolonged Prolonged Platelets aggregation test (Collagen, ADP, Thrombin) Normal Normal Abnormal Ristocetin Aggregation test Abnormal Normalises after the addition of normal serum . Abnormal Doesn\u2019t normalise after the addition of normal serum . Normal vWF factor levels Decreased Normal Normal PT and aPTT Normal PT and prolonged aPTT Normal Normal MNEMONIC: B comes before G which is why Bernard Soullier shows the absence of Ib and Glanzmann Thrombasthenia shows the absence of IIb .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Severe factor seven deficiency. PT increased. Option: B. Liver failure. PT increased. Option: D. DIC. PT increased.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cf301181",
      "audio": ""
    },
    {
      "text": "The clinical presentation of platelet-related bleeding may include all of the following except:",
      "options": [
        {
          "label": "A",
          "text": "Bruising",
          "correct": false
        },
        {
          "label": "B",
          "text": "Nosebleeds",
          "correct": false
        },
        {
          "label": "C",
          "text": "Gastrointestinal bleeding",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bleeding into the joints (hemarthroses)",
          "correct": true
        }
      ],
      "correct_answer": "D. Bleeding into the joints (hemarthroses)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Bleeding into the joints (hemarthroses) Bleeding into the joints (hemarthroses) is a feature of a coagulation factor deficiency and not platelet defects</p>\n<p><strong>Highyeild:</strong></p><p>Hemophilia A (Factor VIII Deficiency) Hemophilia A, the most common hereditary disease associated with life-threatening bleeding , is caused by mutations in factor VIII , an essential cofactor for factor IX in the coagulation cascade. Hemophilia A is inherited as an X-linked recessive trait and thus affects mainly males and homozygous females . In all symptomatic cases, there is a tendency toward easy bruising and massive haemorrhage after trauma or operative procedures. In addition, spontaneous haemorrhages frequently occur in regions of the body that are susceptible to trauma, particularly the joints , where they are known as hemarthroses . Recurrent bleeding into the joints leads to progressive deformities that can be crippling. Petechiae are characteristically absent .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Bruising. Correct . Option: B. Nosebleeds. Correct . Option: C. Gastrointestinal bleeding. Correct .</p>\n<p><strong>Extraedge:</strong></p><p>Patients with haemophilia A have a prolonged PTT and a normal PT , results that point to an abnormality of the intrinsic coagulation pathway. Hemophilia A is treated with infusions of recombinant factor VIII .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5e14717e",
      "audio": ""
    },
    {
      "text": "Rapid assessment of the entire coagulation pathway can be done by:",
      "options": [
        {
          "label": "A",
          "text": "Thromboelastography",
          "correct": true
        },
        {
          "label": "B",
          "text": "Clotting Time",
          "correct": false
        },
        {
          "label": "C",
          "text": "aPTT",
          "correct": false
        },
        {
          "label": "D",
          "text": "Prothrombin Time",
          "correct": false
        }
      ],
      "correct_answer": "A. Thromboelastography",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Thromboelastography Rapid assessment of the entire coagulation pathway can be done by thromboelastography.</p>\n<p><strong>Highyeild:</strong></p><p>Thromboelastography (TEG): Rapid assessment of the entire coagulation pathway can be done by: Thromboelastography. table,tr,th,td {border:1px solid black;} TEG What is it? Normal values Abnormality in TEG Treatment R-value Reaction time: Time between initiation of coagulation cascade to initial formation of the clot 5-10 min Abnormality of Coagulation factors FFP K value Kinetic time: Time between the initial formation of the clot to specific clot firmness (20mm) 1-3 min Abnormality of Fibrinogen Cryoprecipitate \u03b1 angle Rate of Clot formation & crosslinking, steeper the angle faster the rate of clot formation 53-72\u00b0 Abnormality of Fibrinogen Cryoprecipitate MA Maximum Amplitude: Maximum clot strength, depends on Platelets 50-70mm Abnormality of Platelets Platelets Ly-30 Fibrinolysis after 30 min of MA 0-8% Excess Fibrinolysis Aminocaproic acid & Tranexamic acid</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: B. Clotting Time. Incorrect Option: C. aPTT. Measures Intrinsic pathway of coagulation . Option: D. Prothrombin Time. Measures extrinsic pathway of coagulation .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bb497a3d",
      "audio": ""
    },
    {
      "text": "What does the marked area 'E' represent and what will be the management?",
      "options": [
        {
          "label": "A",
          "text": "MA, Maximum clot strength, platelet transfusion",
          "correct": false
        },
        {
          "label": "B",
          "text": "K, Kinetic time: Time between the initial formation of the clot to specific clot firmness (20mm), Cryoprecipitate transfusion",
          "correct": true
        },
        {
          "label": "C",
          "text": "R, Reaction time: Time between initiation of coagulation cascade to initial formation of a clot, FFP transfusion",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ly-30, Fibrinolysis after 30 min of MA, Tranexamic acid",
          "correct": false
        }
      ],
      "correct_answer": "B. K, Kinetic time: Time between the initial formation of the clot to specific clot firmness (20mm), Cryoprecipitate transfusion",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>K, Kinetic time: Time between the initial formation of the clot to specific clot firmness (20mm), Cryoprecipitate transfusion Marked areas in the image represent A: R, Reaction time: Time between initiation of coagulation cascade to initial formation of a clot, FFP transfusion. B: K, Kinetic time: Time between the initial formation of the clot to specific clot firmness (20mm), Cryoprecipitate transfusion. C: \u03b1 angle, Rate of Clot formation & crosslinking, steeper angle faster is the rate of clot formation, Cryoprecipitate transfusion. D: MA, Maximum clot strength, platelet transfusion. E: Ly-30, Fibrinolysis after 30 min of MA, Tranexamic acid.</p>\n<p><strong>Highyeild:</strong></p><p>Thromboelastography (TEG): Rapid assessment of the entire coagulation pathway can be done by: Thromboelastography. table,tr,th,td {border:1px solid black;} TEG What is it? Normal values Abnormality in TEG Treatment R-value Reaction time: Time between initiation of coagulation cascade to initial formation of a clot 5-10 min Abnormality of Coagulation factors FFP K value Kinetic time: Time between the initial formation of the clot to specific clot firmness (20mm) 1-3 min Abnormality of Fibrinogen Cryoprecipitate \u03b1 angle Rate of Clot formation & crosslinking, steeper the angle faster the rate of clot formation 53-72\u00b0 Abnormality of Fibrinogen Cryoprecipitate MA Maximum Amplitude: Maximum clot strength, depends on Platelets 50-70mm Abnormality of Platelets Platelets Ly-30 Fibrinolysis after 30 min of MA 0-8% Excess Fibrinolysis Aminocaproic acid & Tranexamic acid</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. MA, Maximum clot strength, platelet transfusion. Represented by \u2018 D \u2019 in the image. Option: B. K, Kinetic time: Time between the initial formation of the clot to specific clot firmness (20mm), Cryoprecipitate transfusion. Represented by \u2018 B \u2019 in the image. Option: C. R, Reaction time: Time between initiation of coagulation cascade to initial formation of a clot, FFP transfusion. Represented by \u2018 A \u2019 in the image.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cd78975c",
      "audio": ""
    },
    {
      "text": "You are an intern working at AIIMS casualty, a 24-year-old male came with a life-threatening RTA with a fracture of the base of the skull, and several injuries noted on the face, arms and torso. The patient's GCS is 8, BP is 90/60 mmHg and pulse is 120. The patient was given fluids and stabilised, his blood investigations were sent and are awaited. Your SR gave you the following Thromboelastography to interpret for this patient.",
      "options": [
        {
          "label": "A",
          "text": "MA is decreased, consider transfusing platelets",
          "correct": true
        },
        {
          "label": "B",
          "text": "MA is increased, consider transfusing platelets",
          "correct": false
        },
        {
          "label": "C",
          "text": "MA is decreased, consider transfusing FFP",
          "correct": false
        },
        {
          "label": "D",
          "text": "MA is increased, consider transfusing FFP",
          "correct": false
        }
      ],
      "correct_answer": "A. MA is decreased, consider transfusing platelets",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>MA is decreased, consider transfusing platelets In the given image, the \u2018 Test tube \u2019 pattern of TEG is seen, suggesting MA is decreased , thus platelet transfusion should be considered.</p>\n<p><strong>Highyeild:</strong></p><p>Thromboelastography (TEG): Rapid assessment of the entire coagulation pathway can be done by: Thromboelastography. table,tr,th,td {border:1px solid black;} TEG What is it? Normal values Abnormality in TEG Treatment R-value Reaction time: Time between initiation of coagulation cascade to initial formation of a clot 5-10 min Abnormality of Coagulation factors FFP K value Kinetic time: Time between the initial formation of the clot to specific clot firmness (20mm) 1-3 min Abnormality of Fibrinogen Cryoprecipitate \u03b1 angle Rate of Clot formation & crosslinking, steeper the angle faster the rate of clot formation 53-72\u00b0 Abnormality of Fibrinogen Cryoprecipitate MA Maximum Amplitude: Maximum clot strength, depends on Platelets 50-70mm Abnormality of Platelets Platelets Ly-30 Fibrinolysis after 30 min of MA 0-8% Excess Fibrinolysis Aminocaproic acid & Tranexamic acid</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: B. MA is increased, consider transfusing platelets. False, MA is decreased , not increased. Option: C. MA is decreased, consider transfusing FFP. False, Platelets are transfused when MA is decreased , not FFP. Option: D. MA is increased, consider transfusing FFP. False, MA is decreased , not increased.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5d57f4c9",
      "audio": ""
    }
  ]
}